GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Gastroenterology Advisor

Imfinzi-Based Perioperative Regimen Approved for Gastric/GEJ Cancers

The FDA approved perioperative durvalumab with FLOT chemotherapy for eligible patients with resectable Stage II-IVA gastric and GEJ cancers.

Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth

AbbVie is also developing oncology therapies beyond ADC. A key candidate in the company’s pipeline is etentamig/ABBV-383, a ...

AstraZeneca: A Rare Compound Growth Opportunity In Biopharma

AstraZeneca PLC is rated a Buy due to strong growth, prudent R&D reinvestment, low leverage and resilience. Learn more about ...
The Caledonian-Record

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

OCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the ...
Kalkine Media

AstraZeneca PLC (NASDAQ:AZN) Nasdaq Futures Science-Driven Growth

AstraZeneca PLC (NASDAQ:AZN) operates across global healthcare markets through advanced research pathways, biopharmaceutical ...
MyChesCo on MSN

AstraZeneca wins landmark approval for IMFINZI regimen in early gastric cancer

WILMINGTON, DE — AstraZeneca secured U.S. approval for its IMFINZI (durvalumab) regimen in combination with FLOT chemotherapy ...